首页 | 本学科首页   官方微博 | 高级检索  
检索        

依折麦布改善PCI术后患者血脂代谢和预后的临床效果
引用本文:赵宝莲,王崇振.依折麦布改善PCI术后患者血脂代谢和预后的临床效果[J].心脏杂志,2018,30(6):687-690.
作者姓名:赵宝莲  王崇振
作者单位:陕西省第四人民医院心血管内科, 陕西 西安 710043
摘    要:目的 观察依折麦布联合阿托伐他汀对经皮冠状动脉介入(PCI)治疗术后患者血脂代谢和预后的临床效果。 方法 根据患者降脂治疗方案不同,将PCI术后患者随机分为依折麦布联合阿托伐他汀组(联合治疗组)和单用阿托伐他汀组(阿托伐他汀组)各90例,患者降脂治疗前后均行检测血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和血清高敏C反应蛋白(hs-CRP)水平,比较两组患者TC、LDL-C和hs-CRP的变化,同时比较两组主要不良心脑血管事件(MACCE)发生情况。 结果 两组血清TC、LDL-C和hs-CRP均较治疗前显著降低,联合治疗组血清TC(3.0±0.8)mmol/L vs.(4.2±0.9)mmol/L,P<0.05]、LDL-C(2.0±0.8)mmol/L vs.(2.4±1.0)mmol/L,P<0.05]和hs-CRP(2.6±5.0)mg/L vs.(3.7±4.5)mg/L,P<0.05]较阿托伐他汀组降低更显著(均P<0.05)。联合治疗组患者MACCE发生率显著低于阿托伐他汀组7%vs.18%,P<0.05]。 结论 依折麦布联合阿托伐他汀可更好改善PCI术后患者的血清TC、LDL-C和hs-CRP水平,同时减少短期MACCE发生率,有较好的临床应用价值。

关 键 词:依折麦布    阿托伐他汀    经皮冠状动脉介入术    主要不良心脑血管事件
收稿时间:2018-01-10

Clinical effects of ezetimibe on improving lipid metabolism and prognostic impact in patients after percutaneous coronary intervention surgery
Institution:Department of Cardiology, Fourth People's Hospital of Shaanxi Province, Xi'an 710043, Shaanxi, China
Abstract:AIM To observe the effect of ezetimibe combined with atorvastatin on blood lipid metabolism and prognostic impact in patients after percutaneous coronary intervention (PCI) surgery. METHODS 180 patients were randomly divided into a combined treatment group and an atorvastatin group. Changes were measured in serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and serum high sensitive C reactive protein (hs-CRP) and compared between the two groups in six months after treatment. The changes were compared with the incidence of major adverse cardiac cerebral vascular events (MACCE) beween the two groups. RESULTS The serum levels of TC, LDL-C and hs-CRP were significantly lower than those before the treatment in both of the two groups, combined treatment group serum TC(3.0±0.8) mmol/L vs.(4.2±0.9) mmol/L, P<0.05], LDL-C(2.0±0.8) mmol/L vs.(2.4±1.0) mmol/L, and hs-CRP(2.6±5.0) mg/L vs.(3.7±4.5) mg/L, P<0.05] decreased significantly compared with atorvastatin group; the incidence of MACCE was significantly lower in combined treatment group than atorvastatin group (7% vs. 18%, P<0.05). CONCLUSION Ezetimibe combined with atorvastatin effectively improve serum TC, LDL-C and hs-CRP levels in patients after PCI surgery, and also reduce the incidence of MACCE, which has better clinical application value.
Keywords:
点击此处可从《心脏杂志》浏览原始摘要信息
点击此处可从《心脏杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号